CAW
ALXN

Cornerstone Advisors (Washington)’s Alexion Pharmaceuticals ALXN Stock Holding History

Cornerstone Advisors (Washington)’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-209
Closed -$27K – 1475
2019
Q2 		$27K Buy
209
+78
+60% +$10.1K ﹤0.01% 582
2019
Q1 		$18K Sell
131
-324
-71% -$40.3K ﹤0.01% 626
2018
Q4 		$44K Sell
455
-77
-14% -$9.1K 0.01% 326
2018
Q3 		$74K Sell
532
-614
-54% -$77K 0.05% 255
2018
Q2 		$142K Sell
1,146
-98
-8% -$11.5K 0.1% 159
2018
Q1 		$139K Sell
1,244
-125
-9% -$14.9K 0.09% 156
2017
Q4 		$164K Sell
1,369
-230
-14% -$28K 0.11% 139
2017
Q3 		$224K Sell
1,599
-210
-12% -$28.5K 0.15% 93
2017
Q2 		$220K Buy
1,809
+632
+54% +$73.6K 0.12% 91
2017
Q1 		$143K Hold
1,177
– – 0.08% 148
2016
Q4 		$144K Buy
1,177
+213
+22% +$26.1K 0.12% 130
2016
Q3 		$118K Buy
964
+310
+47% +$39.9K 0.1% 150
2016
Q2 		$76K Sell
654
-17
-3% -$2.41K 0.08% 124
2016
Q1 		$93K Buy
671
+70
+12% +$10.3K 0.1% 114
2015
Q4 		$115K Sell
601
-784
-57% -$137K 0.13% 111
2015
Q3 		$217K Sell
1,385
-205
-13% -$37.4K 0.19% 91
2015
Q2 		$287K Buy
1,590
+372
+31% +$64.2K 0.23% 70
2015
Q1 		$211K Hold
1,218
– – 0.16% 105
2014
Q4 		$225K Buy
1,218
+1,209
+13,433% +$224K 0.16% 103
2014
Q3 		$1K Sell
9
-4
-31% -$657 ﹤0.01% 579
2014
Q2 		$2K Hold
13
– – ﹤0.01% 506
2014
Q1 		$2K Buy
+13
New +$2.07K ﹤0.01% 418

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cornerstone Advisors (Washington)'s ALXN Position: Q3 2019 in Review

Cornerstone Advisors (Washington) sold out of Alexion Pharmaceuticals (ALXN) in Q3 2019, closing a stake of 209 shares — an estimated $27K sold.

Cornerstone Advisors (Washington) first reported a position in ALXN in Q1 2014 and held it in 22 quarters. The position peaked at $287K in Q2 2015. 648 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

  • Cornerstone Advisors (Washington) reported no remaining Alexion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Cornerstone Advisors (Washington) sold 209 Alexion Pharmaceuticals shares in Q3 2019, an estimated $27K.
  • Cornerstone Advisors (Washington) first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 22 quarters.
  • Cornerstone Advisors (Washington)'s Alexion Pharmaceuticals position peaked at $287K in Q2 2015.
  • 648 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Cornerstone Advisors (Washington)'s 13F filing for Q3 2019, filed 23 Oct 2019.